Elagolix Sodium

Elagolix is a selective gonadotropin-releasing hormone receptor (GnRHR) antagonist with KD of 54 pM. It is in phase III clinical trials for the treatment of endometriosis and uterine leiomyoma. Elagolix was also under investigation for the treatment of prostate cancer and benign prostatic hyperplasia, but development for these indications was ultimately not pursued.

Price Not Available inquiry Elagolix Sodium Supplier Page

Catalog Number	API832720362
Alternative Name(s)	Elagolix sodium salt Orlissa Elagolix sodium [USAN]
Research Area	APIs for Endometriosis
Molecular Formula	C32H29F5N3NaO5
CAS#	832720-36-2
SMILES	CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)CC(C3=CC=CC=C3)NCCCC(=O)[O-])C4=C(C(=CC=C4)OC)F.[Na+]
Size	inquiry
Supplier Page	https://www.protheragen-ing.com/elagolix-sodium-item-6011.html